Quantcast
Last updated on April 16, 2014 at 21:24 EDT

Latest Nilotinib Stories

2014-01-09 08:28:38

LONDON, Jan. 9, 2014 /PRNewswire/ -- The Avillion Group (Avillion), a co-developer of late-stage clinical assets, announced today that it has entered into an exclusive collaborative development agreement with Pfizer Inc. to conduct a global Phase 3 clinical trial of Pfizer's BOSULIF(®) (bosutinib). The trial, which will be conducted across multiple sites in the United States, Asia and Europe, will evaluate BOSULIF, administered at a starting dose level of 400 mg daily, as a...

2013-12-08 20:20:38

- ENESTnd data indicate trend for longer overall survival and event-free survival in newly diagnosed Ph+ CML patients on Tasigna versus Gleevec(1) EAST HANOVER, N.J., Dec. 8, 2013 /PRNewswire/ -- Findings from three large, randomized Phase III studies demonstrate the superiority of Tasigna(®) (nilotinib) compared to Gleevec(®) (imatinib mesylate) tablets* at achieving deeper molecular responses across various Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) patient...

2012-12-10 16:24:12

EAST HANOVER, N.J., Dec. 10, 2012 /PRNewswire/ -- The latest results from two Phase III clinical trials further establish the benefits of Tasigna(®) (nilotinib) compared to Gleevec(®) (imatinib mesylate) tablets* in the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in newly diagnosed patients and in those with residual disease who switched to Tasigna after long-term treatment with Gleevec. Findings from both studies were presented in oral sessions...

2012-07-25 02:29:04

SUNNYVALE, Calif., July 25, 2012 /PRNewswire/ -- Cepheid (NASDAQ: CPHD) today announced the release of an updated Xpert(®) BCR-ABL Monitor test, now incorporating lot-specific standardization using the WHO (World Health Organization) BCR-ABL standards. The test is being released as a European CE-IVD Mark product under the European Directive on In Vitro Diagnostic Medical Devices. The test, which runs on Cepheid's GeneXpert(®) System, detects the BCR-ABL mRNA transcript in the...

2012-06-17 22:22:09

AMSTERDAM and CAMBRIDGE, Massachusetts, June 18, 2012 /PRNewswire/ -- ~ Robust anti-leukemic activity in CML patients who have become resistant or intolerant to available tyrosine kinase inhibitors ~ 54% major cytogenetic response and 30% major molecular response reported in heavily pre-treated chronic-phase CML patients ~ Data supports ARIAD filing for EMA approval of ponatinib in Europe ARIAD...

2012-06-01 10:22:07

NORTH WALES, Pa., June 1, 2012 /PRNewswire/ -- Teva Oncology presented two secondary analyses today featuring omacetaxine mepesuccinate, an investigational, first-in-class cephalotaxine that functions as a protein synthesis inhibitor at the American Society of Clinical Oncology Annual Meeting, June 1-5, 2012, Chicago. These analyses were derived from data that was submitted to the US Food and Drug Administration as part of a new drug application (NDA) and was recently accepted for review.(4)...

2012-04-17 02:27:47

MONTREAL, April 17, 2012 /PRNewswire/ -The CML Society of Canada commends the Ontario government for the recent decision to add Sprycel (dasatinib) and Tasigna (nilotinib) to the list of CML (chronic myelogenous leukemia) treatments reimbursed in first line, giving patients newly diagnosed with CML more treatment options earlier.  As patient advocates for equal access to all available therapies, the CML Society of Canada feels it is important that governments are aware that it is...

2012-04-05 21:10:02

Researchers reporting in the April Cell Stem Cell, a Cell Press publication, have found a way to stop leukemia stem cells in their tracks. The advance in mice suggests that a combination approach to therapy might stamp out chronic myeloid leukemia (CML) for good. That's in contrast to the vast majority of CML patients taking drugs like imatinib (aka Gleevec) today, who often go into remission only to see their cancer return again. It is those lingering leukemia stem cells, which stubbornly...

2012-02-27 07:26:30

A new study has found that patients with chronic myeloid leukemia (CML) who have not responded to interferon treatments experience long-term benefits when they switch to the targeted drug imatinib. Published early online in Cancer, a peer-reviewed journal of the American Cancer Society, the study indicates that imatinib is the treatment of choice for these patients. Imatinib, a drug that blocks the protein made by a particular cancer-causing gene, has revolutionized the treatment and...

2012-02-13 23:02:08

New research takes aim at stubborn cancer stem cells that are thought to be responsible for treatment resistance and relapse. The study, published by Cell Press in the February 14 issue of the journal Cancer Cell, provides insight into mechanisms associated with the survival of leukemia stem cells and identifies a potential therapeutic target that is specific for these dangerously persistent cells. Chronic myelogenous leukemia (CML) is a cancer of the white blood cells for which tyrosine...